Huynh Huu Hien, Forrest Katrina, Becker Jessica O, Emrick Michelle A, Miller Geoffrey D, Moncrieffe Danielle, Cowan David A, Thomas Andreas, Thevis Mario, MacCoss Michael J, Hoffstrom Ben, Byers Peter H, Eichner Daniel, Hoofnagle Andrew N
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Sports Medicine Research and Testing Laboratory, Salt Lake City, UT, USA.
Clin Chem. 2022 Oct 6;68(10):1281-1291. doi: 10.1093/clinchem/hvac119.
The development of analytical approaches to help reduce the risk of growth hormone (GH) doping is important to fair competition and the health of athletes. However, the reliable detection of GH use remains challenging. The identification of novel biomarkers of GH administration could lead to a better understanding of the physiological response to GH, more sensitive detection of the illicit use of GH in sport, and better management of patients treated for GH disorders.
We developed a targeted liquid chromatography-tandem mass spectrometry method to simultaneously quantify the carboxyl-terminal propeptide of type III procollagen (P-III-CP) and type III collagen degradation products in human serum. Following proteolysis, we instituted a simple acid precipitation step to reduce digested sample complexity before peptide immunoenrichment, which improved the recovery of one target peptide from serum. We evaluated the concentration of each biomarker at different age ranges and after GH administration in healthy participants.
The assay was linear over an estimated concentration range of 0.3 to1.0 nM and 0.1 to 0.4 nM for each surrogate peptide of P-III-CP and collagen fragments, respectively. Intra-day and inter-day coefficients of variation were ≤15%. Biomarker concentrations appeared to vary with age and to reflect age-specific collagen turnover. Moreover, their concentrations changed after GH administration.
Our method quantifies the proteins belonging to the family of P-III-CP and type III collagen degradation products in human serum, which could be used to detect GH administration in athletes and better understand diseases involving GH therapy or altered type III collagen turnover.
开发有助于降低生长激素(GH)兴奋剂使用风险的分析方法对于公平竞争和运动员健康至关重要。然而,可靠检测GH的使用仍然具有挑战性。鉴定GH给药的新型生物标志物可能有助于更好地理解对GH的生理反应,更灵敏地检测体育运动中非法使用GH的情况,并更好地管理接受GH紊乱治疗的患者。
我们开发了一种靶向液相色谱-串联质谱法,用于同时定量人血清中III型前胶原羧基末端前肽(P-III-CP)和III型胶原降解产物。蛋白水解后,我们采用简单的酸沉淀步骤,以降低消化后样品的复杂性,然后进行肽免疫富集,这提高了一种目标肽从血清中的回收率。我们评估了健康参与者在不同年龄范围以及GH给药后的每种生物标志物浓度。
对于P-III-CP和胶原片段的每种替代肽,该测定在估计浓度范围分别为0.3至1.0 nM和0.1至0.4 nM时呈线性。日内和日间变异系数≤15%。生物标志物浓度似乎随年龄变化,并反映特定年龄的胶原周转情况。此外,GH给药后它们的浓度发生了变化。
我们的方法可定量人血清中属于P-III-CP家族和III型胶原降解产物的蛋白质,可用于检测运动员中GH的使用情况,并更好地了解涉及GH治疗或III型胶原周转改变的疾病。